Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders : a report of the IMWG Bone Working Group
Whole Body Low Dose CT (WBLDCT) has important advantages as a first-line imaging modality for bone disease assessment in patients with plasma cell disorders and has been included in the 2014 International Myeloma Working Group (IMWG) criteria for multiple myeloma (MM) definition. Nevertheless, standardization guidelines for the optimal use of WBLDCT in MM patients are still lacking, preventing its more widespread use, both in daily practice and clinical trials. The aim of this report by the Bone Group of the IMWG is to provide practical recommendations for the acquisition, interpretation and reporting of WBLDCT in patients with multiple myeloma and other plasma cell disorders.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Blood cancer journal - 8(2018), 10 vom: 04. Okt., Seite 95 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Moulopoulos, Lia A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 25.04.2019 Date Revised 10.06.2019 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41408-018-0124-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM289231957 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM289231957 | ||
| 003 | DE-627 | ||
| 005 | 20231225062111.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41408-018-0124-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0964.xml |
| 035 | |a (DE-627)NLM289231957 | ||
| 035 | |a (NLM)30287814 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Moulopoulos, Lia A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders |b a report of the IMWG Bone Working Group |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.04.2019 | ||
| 500 | |a Date Revised 10.06.2019 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Whole Body Low Dose CT (WBLDCT) has important advantages as a first-line imaging modality for bone disease assessment in patients with plasma cell disorders and has been included in the 2014 International Myeloma Working Group (IMWG) criteria for multiple myeloma (MM) definition. Nevertheless, standardization guidelines for the optimal use of WBLDCT in MM patients are still lacking, preventing its more widespread use, both in daily practice and clinical trials. The aim of this report by the Bone Group of the IMWG is to provide practical recommendations for the acquisition, interpretation and reporting of WBLDCT in patients with multiple myeloma and other plasma cell disorders | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Koutoulidis, Vassilis |e verfasserin |4 aut | |
| 700 | 1 | |a Hillengass, Jens |e verfasserin |4 aut | |
| 700 | 1 | |a Zamagni, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Aquerreta, Jesus D |e verfasserin |4 aut | |
| 700 | 1 | |a Roche, Charles L |e verfasserin |4 aut | |
| 700 | 1 | |a Lentzsch, Suzanne |e verfasserin |4 aut | |
| 700 | 1 | |a Moreau, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Cavo, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Miguel, Jesus San |e verfasserin |4 aut | |
| 700 | 1 | |a Dimopoulos, Meletios A |e verfasserin |4 aut | |
| 700 | 1 | |a Rajkumar, S Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Durie, Brian G M |e verfasserin |4 aut | |
| 700 | 1 | |a Terpos, Evangelos |e verfasserin |4 aut | |
| 700 | 1 | |a Delorme, Stefan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood cancer journal |d 2011 |g 8(2018), 10 vom: 04. Okt., Seite 95 |w (DE-627)NLM219701628 |x 2044-5385 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2018 |g number:10 |g day:04 |g month:10 |g pages:95 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41408-018-0124-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2018 |e 10 |b 04 |c 10 |h 95 | ||